Alejandro V Villagra

List of Publications by Year
in descending order

58 papers	4,188 citations	136940 32 h-index	149686 56 g-index
64 all docs	64 docs citations	64 times ranked	6030 citing authors

#	Article	IF	Citations
1	The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance. Nature Immunology, 2009, 10, 92-100.	14.5	390
2	HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade. Cancer Immunology Research, 2015, 3, 1375-1385.	3.4	342
3	Epigenetic silencing of retinoblastoma gene regulates pathologic differentiation of myeloid cells in cancer. Nature Immunology, 2013, 14, 211-220.	14.5	306
4	Regulation of the Bone-Specific Osteocalcin Gene by p300 Requires Runx2/Cbfa1 and the Vitamin D3 Receptor but Not p300 Intrinsic Histone Acetyltransferase Activity. Molecular and Cellular Biology, 2003, 23, 3339-3351.	2.3	190
5	Epigenetic therapy for ovarian cancer: promise and progress. Clinical Epigenetics, 2019, 11, 7.	4.1	181
6	Histone deacetylases and the immunological network: implications in cancer and inflammation. Oncogene, 2010, 29, 157-173.	5.9	177
7	Selective Histone Deacetylase 6 Inhibitors Bearing Substituted Urea Linkers Inhibit Melanoma Cell Growth. Journal of Medicinal Chemistry, 2012, 55, 9891-9899.	6.4	153
8	Bone-Specific Transcription Factor Runx2 Interacts with the 1Î±,25-Dihydroxyvitamin D 3 Receptor To Up-Regulate Rat Osteocalcin Gene Expression in Osteoblastic Cells. Molecular and Cellular Biology, 2004, 24, 8847-8861.	2.3	126
9	Essential role of HDAC6 in the regulation of PDâ€Ł1 inÂmelanoma. Molecular Oncology, 2016, 10, 735-750.	4.6	125
10	Divergent roles of histone deacetylase 6 (HDAC6) and histone deacetylase 11 (HDAC11) on the transcriptional regulation of IL10 in antigen presenting cells. Molecular Immunology, 2014, 60, 44-53.	2.2	124
11	Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of immunosuppressive proteins in tumor cells. Scientific Reports, 2019, 9, 6136.	3.3	124
12	Targeting histone deacetylase 6 mediates a dual antiâ€melanoma effect: Enhanced antitumor immunity and impaired cell proliferation. Molecular Oncology, 2015, 9, 1447-1457.	4.6	111
13	A Novel Role for Histone Deacetylase 6 in the Regulation of the Tolerogenic STAT3/IL-10 Pathway in APCs. Journal of Immunology, 2014, 193, 2850-2862.	0.8	106
14	Targeting the Fanconi Anemia/BRCA Pathway Circumvents Drug Resistance in Multiple Myeloma. Cancer Research, 2009, 69, 9367-9375.	0.9	100
15	The ATDC (TRIM29) Protein Binds p53 and Antagonizes p53-Mediated Functions. Molecular and Cellular Biology, 2010, 30, 3004-3015.	2.3	98
16	Histone deacetylase 11: A novel epigenetic regulator of myeloid derived suppressor cell expansion and function. Molecular Immunology, 2015, 63, 579-585.	2.2	98
17	Reduced CpG methylation is associated with transcriptional activation of the bone-specific rat osteocalcin gene in osteoblasts*. Journal of Cellular Biochemistry, 2002, 85, 112-122.	2.6	93
18	Immunoepigenetics Combination Therapies: An Overview of the Role of HDACs in Cancer Immunotherapy. International Journal of Molecular Sciences, 2019, 20, 2241.	4.1	93

#	Article	IF	Citations
19	The antimelanoma activity of the histone deacetylase inhibitor panobinostat (LBH589) is mediated by direct tumor cytotoxicity and increased tumor immunogenicity. Melanoma Research, 2013, 23, 341-348.	1.2	89
20	Ligand-Independent EPHA2 Signaling Drives the Adoption of a Targeted Therapyâ€“Mediated Metastatic Melanoma Phenotype. Cancer Discovery, 2015, 5, 264-273.	9.4	82
21	Histone Deacetylase 8 Safeguards the Human Ever-Shorter Telomeres 1B (hEST1B) Protein from Ubiquitin-Mediated Degradation. Molecular and Cellular Biology, 2006, 26, 5259-5269.	2.3	78
22	Combining DNMT and HDAC6 inhibitors increases anti-tumor immune signaling and decreases tumor burden in ovarian cancer. Scientific Reports, 2020, 10, 3470.	3.3	72
23	Chromatin Remodeling and Transcriptional Activity of the Bone-specific Osteocalcin Gene Require CCAAT/Enhancer-binding Protein Î²-dependent Recruitment of SWI/SNF Activity*. Journal of Biological Chemistry, 2006, 281, 22695-22706.	3.4	71
24	c-Abl Stabilizes HDAC2 Levels by Tyrosine Phosphorylation Repressing Neuronal Gene Expression in Alzheimerâ€™s Disease. Molecular Cell, 2014, 56, 163-173.	9.7	71
25	Discovery of a New Isoxazole-3-hydroxamate-Based Histone Deacetylase 6 Inhibitor SS-208 with Antitumor Activity in Syngeneic Melanoma Mouse Models. Journal of Medicinal Chemistry, 2019, 62, 8557-8577.	6.4	61
26	Modulation of antigenâ€presenting cells by HDAC inhibitors: implications in autoimmunity and cancer. Immunology and Cell Biology, 2012, 90, 55-65.	2.3	59
27	T cells lacking HDAC11 have increased effector functions and mediate enhanced alloreactivity in a murine model. Blood, 2017, 130, 146-155.	1.4	54
28	Histone Deacetylase Inhibitor LAQ824 Augments Inflammatory Responses in Macrophages through Transcriptional Regulation of IL-10. Journal of Immunology, 2011, 186, 3986-3996.	0.8	50
29	TLR5 ligation by flagellin converts tolerogenic dendritic cells into activating antigen-presenting cells that preferentially induce T-helper 1 responses. Immunology Letters, 2009, 125, 114-118.	2.5	47
30	Epigenetic Regulation of a Brain-specific Glycosyltransferase N-Acetylglucosaminyltransferase-IX (GnT-IX) by Specific Chromatin Modifiers. Journal of Biological Chemistry, 2014, 289, 11253-11261.	3.4	44
31	Essential role for histone deacetylase 11 (HDAC11) in neutrophil biology. Journal of Leukocyte Biology, 2017, 102, 475-486.	3.3	44
32	Targeting Macrophages as a Therapeutic Option in Coronavirus Disease 2019. Frontiers in Pharmacology, 2020, 11, 577571.	3.5	40
33	Tet-Mediated DNA Demethylation Is Required for SWI/SNF-Dependent Chromatin Remodeling and Histone-Modifying Activities That Trigger Expression of the Sp7 Osteoblast Master Gene during Mesenchymal Lineage Commitment. Molecular and Cellular Biology, 2017, 37, .	2.3	31
34	HDAC6 Plays a Noncanonical Role in the Regulation of Antitumor Immune Responses, Dissemination, and Invasiveness of Breast Cancer. Cancer Research, 2020, 80, 3649-3662.	0.9	30
35	Rational Design of Suprastat: A Novel Selective Histone Deacetylase 6 Inhibitor with the Ability to Potentiate Immunotherapy in Melanoma Models. Journal of Medicinal Chemistry, 2020, 63, 10246-10262.	6.4	29
36	Histone Deacetylase 3 Down-regulates Cholesterol Synthesis through Repression of Lanosterol Synthase Gene Expression. Journal of Biological Chemistry, 2007, 282, 35457-35470.	3.4	28

#	Article	IF	Citations
37	Synthesis and Pharmacological Evaluation of Selective Histone Deacetylase 6 Inhibitors in Melanoma Models. ACS Medicinal Chemistry Letters, 2017, 8, 1031-1036.	2.8	25
38	Indocyanine Green-Nexturastat A-PLGA Nanoparticles Combine Photothermal and Epigenetic Therapy for Melanoma. Nanomaterials, 2020, 10, 161.	4.1	25
39	SWI/SNF-Independent Nuclease Hypersensitivity and an Increased Level of Histone Acetylation at the P1 Promoter Accompany Active Transcription of the Bone Master Gene Runx2. Biochemistry, 2009, 48, 7287-7295.	2.5	24
40	Stat3 Inhibition Augments the Immunogenicity of B-cell Lymphoma Cells, Leading to Effective Antitumor Immunity. Cancer Research, 2012, 72, 4440-4448.	0.9	17
41	Functional Analysis of HDACs in Tumorigenesis. Methods in Molecular Biology, 2019, 1983, 279-307.	0.9	17
42	Silencing of HDAC6 as a therapeutic target in chronic lymphocytic leukemia. Blood Advances, 2018, 2, 3012-3024.	5.2	16
43	Use of nanocrystalline diamond for microfluidic lab-on-a-chip. Diamond and Related Materials, 2006, 15, 2073-2077.	3.9	14
44	CD137 agonist potentiates the abscopal efficacy of nanoparticle-based photothermal therapy for melanoma. Nano Research, 2022, 15, 2300-2314.	10.4	12
45	Circumventing Immune Tolerance Through Epigenetic Modification. Current Pharmaceutical Design, 2010, 16, 268-276.	1.9	11
46	Histone Deacetylase 6 (HDAC6) As a Regulator of Immune Check-Point Molecules in Chronic Lymphocytic Leukemia (CLL). Blood, 2014, 124, 3311-3311.	1.4	11
47	Functional Analysis of Histone Deacetylase 11 (HDAC11). Methods in Molecular Biology, 2016, 1436, 147-165.	0.9	8
48	Phase I trial of histone deacetylase inhibitor panobinostat in addition to glucocorticoids for primary therapy of acute graft-versus-host disease. Bone Marrow Transplantation, 2018, 53, 1434-1444.	2.4	8
49	Enhancing Therapeutic Approaches for Melanoma Patients Targeting Epigenetic Modifiers. Cancers, 2021, 13, 6180.	3.7	8
50	Expression and Function of Histone Deacetylase 10 (HDAC10) in B Cell Malignancies. Methods in Molecular Biology, 2016, 1436, 129-145.	0.9	7
51	Tipifarnib-mediated suppression of T-bet-dependent signaling pathways. Cancer Immunology, Immunotherapy, 2012, 61, 523-533.	4.2	4
52	Preparation and Biochemical Analysis of Classical Histone Deacetylases. Methods in Enzymology, 2016, 573, 161-181.	1.0	3
53	Editorial: Genetic and Epigenetic Control of Immune Responses. Frontiers in Immunology, 2021, 12, 775101.	4.8	2
54	Epigenetic Approaches. , 2013, , 353-372.		1

#	Article	IF	Citations
55	Regulation of the Jak/STATs Pathways by Histone Deacetylases. Cancer Drug Discovery and Development, 2014, , 155-187.	0.4	1
56	Molecular Pathways in Antigen-Presenting Cells Involved in the Induction of Antigen-specific T-cell Tolerance. , 2014, , 411-433.		1
57	DNA Methylation and Histone Modifications in Autoimmunity. , 2018, , 57-86.		0
58	Signaling Pathways in Antigen-Presenting Cells Involved in the Induction of Antigen-Specific T-Cell Tolerance. , 2008, , 197-218.		0